TRITON and beyond: new insights into the profile of prasugrel. - Wikidata - thesis-toulmin - TriplyDB

TRITON and beyond: new insights into the profile of prasugrel.

TRITON and beyond: new insights into the profile of prasugrel.

http://www.wikidata.org/entity/Q37925009

about

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls Clinical diseases with thrombotic risk and their pharmacologycal treatment: how they change the therapeutic attitude in dental treatments.Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry.

P2860

Q26775125-DDC98ECF-C3AB-4F14-B4BB-C1D574AC6D84 Q37370565-FA5EF10E-448F-4600-8A37-0C2EF9D7CDCB Q47213003-A0105E81-E42A-41D3-B269-6B61710C84CF

P2860

TRITON and beyond: new insights into the profile of prasugrel.

http://www.wikidata.org/entity/Q37925009

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

TRITON and beyond: new insights into the profile of prasugrel.

@en

TRITON and beyond: new insights into the profile of prasugrel.

@nl

type

label

TRITON and beyond: new insights into the profile of prasugrel.

@en

TRITON and beyond: new insights into the profile of prasugrel.

@nl

prefLabel

TRITON and beyond: new insights into the profile of prasugrel.

@en

TRITON and beyond: new insights into the profile of prasugrel.

@nl

P1433

Q37925009-97FFB4AE-56CA-47A5-BA0F-6997D1BB73FC

P1476

Q37925009-FC196EB4-5EBC-4AF5-9142-C32C9AECB6C5

P2093

Q37925009-3FE44E61-6EA6-4E95-BA03-BA01CF77D04B

Q37925009-45AEF024-1566-4BFD-B4DB-8C1F976F9FA5

Q37925009-9A2BC7B7-A23C-490F-8240-1DE412EDB086

Q37925009-CC076CF3-DC13-412F-AD36-93D89156E8DB

Q37925009-D829462C-078F-46F2-B3EC-A835C9B3925E

P275

Q37925009-9BE11B74-D6E9-41B1-AE05-DEE8C83FF74C

P2860

Q37925009-05FE6426-D1C2-40B0-B1EC-FF02289D26DF

Q37925009-0A22BBDA-1122-4912-8234-1410962CD3D9

Q37925009-0CA088AF-32B6-4232-9E18-3753FB402F97

Q37925009-120406E6-093F-4F51-8BB8-30A19B0EF690

Q37925009-12AB2E84-7A64-4C62-98AB-6AE8A7931E5D

Q37925009-1852744A-BE2A-490B-94FA-EA546318BA04

Q37925009-220EACFB-3205-457C-95BC-FA382D5801C6

Q37925009-24C0B517-FB5E-40F6-A5D8-C0B9D1CF2D9C

Q37925009-282BB5F5-A703-4CDF-9E59-28B269CE942B

Q37925009-2A290D20-A765-4490-B693-8CF53CFF8734

P304

Q37925009-60FDE44F-0C20-4C45-BFBE-89EC8AAFE3DF

P31

Q37925009-81CF91A7-81AD-4383-852C-EE0520B20349

Q37925009-ADC06BB3-A489-4C41-93A0-BD66049E19A8

P356

Q37925009-C86BF5CB-1A14-4B14-85A3-B429D819660B

P433

Q37925009-4F433799-9C40-48AD-91F5-925FD93C8306

P478

Q37925009-CC00155E-0B98-4B06-B9C0-8DD1A000339F

P577

Q37925009-1CD534FC-2EF2-4313-9079-53885AC4481F

Q37925009-8BAA3599-98D7-43AD-AF9F-5A5E0DB6A4A3

P5875

Q37925009-4EDC9BA3-103A-4E01-A341-6E9AE54EF6B5

P698

Q37925009-D408E9A7-27AE-4F35-9DD7-4ECCB47F846A

P921

Q37925009-7BA19BFB-F7A8-43F8-923A-D78E671A882C

Q37925009-93831946-A729-4626-AF74-E49366624942

P932

Q37925009-136AE601-ED5B-4D7D-9D6A-EAEFBB508A70

P356

J.1755-5922.2011.00263.X

P1433

Cardiovascular Therapeutics

P1476

TRITON and beyond: new insights into the profile of prasugrel.

@en

P2093

Amy G Leishman

http://www.w3.org/2001/XMLSchema#string

David Erlinge

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Riesmeyer

http://www.w3.org/2001/XMLSchema#string

Joseph A Jakubowski

http://www.w3.org/2001/XMLSchema#string

Sandra L Close

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

P304

e174-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-5922.2011.00263.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51612328

http://www.w3.org/2001/XMLSchema#string

P698

21883999

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

biomedical investigative technique

P932

3440581

http://www.w3.org/2001/XMLSchema#string